ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 135 filers reported holding ROYALTY PHARMA PLC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,027,303 | -48.5% | 74,698 | -41.7% | 0.00% | 0.0% |
| Q2 2023 | $3,938,931 | +192.8% | 128,137 | +243.2% | 0.00% | 0.0% |
| Q1 2023 | $1,345,108 | +22.4% | 37,333 | +34.2% | 0.00% | 0.0% |
| Q4 2022 | $1,099,288 | +46.8% | 27,816 | +49.1% | 0.00% | – |
| Q3 2022 | $749,000 | +208.2% | 18,650 | +222.1% | 0.00% | – |
| Q2 2022 | $243,000 | -97.5% | 5,790 | -97.7% | 0.00% | -100.0% |
| Q1 2022 | $9,703,000 | -47.8% | 249,072 | -46.6% | 0.00% | -40.0% |
| Q4 2021 | $18,580,000 | -10.3% | 466,259 | -18.7% | 0.01% | -37.5% |
| Q3 2021 | $20,725,000 | +150.3% | 573,465 | +183.9% | 0.01% | +166.7% |
| Q2 2021 | $8,280,000 | -63.7% | 202,007 | -61.4% | 0.00% | -72.7% |
| Q1 2021 | $22,816,000 | +210.8% | 523,037 | +256.6% | 0.01% | +175.0% |
| Q4 2020 | $7,342,000 | +1201.8% | 146,691 | +994.7% | 0.00% | – |
| Q3 2020 | $564,000 | -72.6% | 13,400 | -68.4% | 0.00% | -100.0% |
| Q2 2020 | $2,060,000 | – | 42,425 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $106,824,000 | 67.12% |
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $269,465,000 | 56.37% |
| Vantage Consulting Group Inc | 4,601,152 | $183,355,000 | 49.30% |
| Indie Asset Partners, LLC | 805,982 | $32,118,000 | 23.31% |
| HARVARD MANAGEMENT CO INC | 3,464,990 | $138,080,000 | 12.96% |
| Brown University | 621,759 | $24,777,000 | 6.04% |
| Overbrook Management Corp | 729,125 | $29,056,000 | 5.86% |
| Bleichroeder LP | 824,033 | $32,838,000 | 5.13% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $7,998,000 | 3.81% |
| Lagoda Investment Management, L.P. | 140,435 | $5,596,000 | 2.65% |